13 completed. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 5 | Completed 5 |
Follow Bronchiectasis: new trials by email Literature Review of Bronchiectasis trials Research Report on Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance RCT1100 - Primary Ciliary Dyskinesia (PCD) | Phase 1 | Completed | ReCode Therapeutics | 14 | 2024-10-22 | 2026-04-30 |
| A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 7 | 2024-09-20 | 2025-10-08 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis CHF6333, CHF6333 Placebo - Bronchiectasis | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 108 | 2023-11-29 | 2026-10-26 |
| Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 9 | 2023-02-18 | 2025-04-29 |
| Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis Bronchial basal cells (BBCs), Bronchoscopic airway clearance treatment (B-ACT) - Bronchiectasis | Phase 1 / Phase 2 | Completed | Ruijin Hospital | 37 | 2020-06-21 | 2023-12-05 |
| Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis hMSCs - Bronchiectasis | Phase 1 | Completed | Marilyn Glassberg | 6 | 2016-02-04 | 2019-08-28 |
| Inhalation Flow Rate-study T-326 Inhaler - Bronchiectasis | Phase 1 | Completed | Bayer | 33 | 2015-11-23 | 2017-04-26 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Molgramostim, Placebo - Pulmonary Alveolar Proteinosis, Bronchiectasis | Phase 1 | Completed | Savara Inc. | 42 | 2015-05-01 | 2017-02-23 |
| Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis Tobramycin - Bronchiectasis | Phase 1 / Phase 2 | Completed | University Medical Center Groningen | 8 | 2013-10-01 | 2014-12-16 |
| A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra) - Asthma, Bronchiectasis | Phase 1 | Completed | Ansun Biopharma, Inc. | 11 | 2010-07-01 | 2019-03-27 |
| Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis Exercise - Bronchiectasis | Phase 1 | Completed | Bayside Health | 39 | 2009-02-01 | 2014-03-11 |
| High Dose Inhaled Mannitol Study mannitol - Bronchiectasis | Phase 1 / Phase 2 | Completed | Syntara | 10 | 2009-01-01 | 2010-02-26 |
| A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device dry powder inhaled mannitol - Healthy, Bronchiectasis | Phase 1 / Phase 2 | Completed | Syntara | 15 | 2008-08-01 | 2009-09-18 |
Ciliary Motility Disorders (3) · Kartagener Syndrome (3) · Asthma (1) · Cystic Fibrosis (1) · Lung Diseases, Interstitial (1) · Pulmonary Alveolar Proteinosis (1) · Respiratory Distress Syndrome (1)
Bronchial Diseases (13) · Respiratory Tract Diseases (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Abnormalities, Multiple (3) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3) · Ciliopathies (3) · Congenital Abnormalities (3) · Dextrocardia (3) · Heart Defects, Congenital (3) · Heart Diseases (3) · Lung Diseases (3) · Otorhinolaryngologic Diseases (3)
Colony-Stimulating Factors (1) · Exercise (1) · Mannitol (1) · Tobramycin (1) · molgramostim (1) · regramostim (1)
ReCode Therapeutics (3) · Syntara (2) · Ansun Biopharma, Inc. (1) · Bayer (1) · Bayside Health (1) · Chiesi Farmaceutici S.p.A. (1) · Marilyn Glassberg (1) · Ruijin Hospital (1) · Savara Inc. (1) · University Medical Center Groningen (1)
Australia (4) · United Kingdom (4) · United States (4) · Germany (2) · China (1) · Denmark (1) · Netherlands (1) · New Zealand (1)
John Matthews, MBBS, MCRP, PhD (3) · Annemarie L Lee, PhD (1) · Glassberg K Marilyn, MD (1) · Heymut Omran, MD (1) · Huib Kerstjens, MD, PhD (1) · James D. Chalmers (1) · Johnston Steward, MD (1) · Kenneth Olivier, MD, MPH, LCID, NIAID (1) · Kim G Nielsen, Dr Med Sci (1) · Michael Loebinger, MD (1) · Ronald Moss, MD (1) · Yun Feng, M.D., Ph.D (1)
PMID 20122281, PMID 24731015, PMID 26252343, PMID 26830468, PMID 28193704, PMID 30848695, PMID 39566467, PMID 40973220